Os objetivos para o tratamento dos pacientes com diabetes tipo 2 envolvem a busca da meta glicêmica adequada, a melhora na qualidade de vida e a prevenção ou o atraso no surgimento das complicações crônicas.

Nesta aula, o Dr. João Paulo Iazigi (CRM 82669/SP) aborda as barreiras para a intensificação do tratamento do diabetes e, por meio de um caso clínico, discute o uso de Soliqua para o atingimento do controle glicêmico de forma eficaz e com efeitos colaterais toleráveis.


  1. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM.

    Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study.

    Diabet Med. 2012 May;29(5):682-9.

  2. Karter AJ, Subramanian U, Saha C, Crosson JC, Parker MM, Swain BE, et al.

    Barriers to insulin initiation: the translating research into action for diabetes insulin starts project.

    Diabetes Care. 2010 Apr;33(4):733-5.

  3. Khunti K, Davies MJ, Kalra S.

    Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care.

    Diabetes Obes Metab. 2013 Aug;15(8):690-700.

  4. Simon AC, Gude WT, Holleman F, Hoekstra JB, Peek N.

    Diabetes patients' experiences with the implementation of insulin therapy and their perceptions of computer-assisted self-management systems for insulin therapy.

    J Med Internet Res. 2014 Oct 23;16(10):e235.

  5. Zambanini A, Newson RB, Maisey M, Feher MD.

    Injection related anxiety in insulin-treated diabetes.

    Diabetes Res Clin Pract. 1999 Dec;46(3):239-46.

  6. Ross SA, Tildesley HD, Ashkenas J.

    Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes.

    Curr Med Res Opin. 2011 Nov;27 Suppl 3:13-20.

  7. Bayoumy IE, Dawood W.

    Identifying and Addressing the Barriers of Insulin Use in Type II Diabetes Patients.

    Diabetes and Metabolic Research. 2018: 38-46.

  8. Petznick AM.

    Identifying and addressing barriers to insulin acceptance and adherence in patients with type 2 diabetes mellitus.

    J Am Osteopath Assoc. 2013 Apr;113(4 Suppl 2):S6-16.

  9. Bin Rsheed A, Chenoweth I.

    Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome.

    World J Diabetes. 2017;8(1):28-39.

  10. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al.

    Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

    Diabetes Care. 2018 Dec;41(12):2669-701.

  11. Davies M, Russell-Jones D, Barber TM, Baradez C, Baxter MA, McCrimmon RJ.

    iGlarLixi fixed-ratio combination in patients with HbA1C >9%: LixiLan-O subgroup analysis. Presented at the 77th Scientific Sessions of the American Diabetes Association, June 9-13, 2017, San Diego, California; abstract 137-LB.

    Disponível em: https://ada.scientificposters.com/epsAbstractADA.cfm?id=6. Acesso em: 12 abr. 2020.

  12. Aroda VR, Rosenstock J, Wysham C, Unger J, Bellido D, González-Gálvez G, et al.

    LixiLan-L Trial Investigators. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.

    Diabetes Care. 2017 Jun;40(6):809.